# Cytoreductive Surgery and HIPEC in First or Secondary Platinum-resistant Recurrent Ovarian Epithelial Cancer

> **NCT03220932** · PHASE3 · UNKNOWN · sponsor: **Hospices Civils de Lyon** · enrollment: 132 (estimated)

## Conditions studied

- Ovarian Epithelial Cancer

## Interventions

- **PROCEDURE:** Cytoreductive surgery combined with HIPEC
- **DRUG:** Chemotherapy and bevacizumab (CT-BEV)

## Key facts

- **NCT ID:** NCT03220932
- **Lead sponsor:** Hospices Civils de Lyon
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-11-30
- **Primary completion:** 2022-11-30
- **Final completion:** 2022-11-30
- **Target enrollment:** 132 (ESTIMATED)
- **Last updated:** 2019-11-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03220932

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03220932, "Cytoreductive Surgery and HIPEC in First or Secondary Platinum-resistant Recurrent Ovarian Epithelial Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03220932. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*